AI assistant
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2022
Feb 15, 2022
7082_dirs_2022-02-15_4f9f8ca5-a7bd-4db1-8047-1b5e69aa6c18.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2022-02-13
Reporting Person: Kalif Eliyahu Sharon (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-13 | Ordinary Shares | M | 6629 | — | Acquired | 25059 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-13 | Restricted Share Units | $ | M | 6629 | Disposed | Ordinary Shares (6629) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022 and February 13, 2023 and 6,630 vesting on February 13, 2024.